Literature DB >> 16522833

Coffee, CYP1A2 genotype, and risk of myocardial infarction.

Marilyn C Cornelis1, Ahmed El-Sohemy, Edmond K Kabagambe, Hannia Campos.   

Abstract

CONTEXT: The association between coffee intake and risk of myocardial infarction (MI) remains controversial. Coffee is a major source of caffeine, which is metabolized by the polymorphic cytochrome P450 1A2 (CYP1A2) enzyme. Individuals who are homozygous for the CYP1A2*1A allele are "rapid" caffeine metabolizers, whereas carriers of the variant CYP1A2*1F are "slow" caffeine metabolizers.
OBJECTIVE: To determine whether CYP1A2 genotype modifies the association between coffee consumption and risk of acute nonfatal MI. DESIGN, SETTING, AND PARTICIPANTS: Cases (n = 2014) with a first acute nonfatal MI and population-based controls (n = 2014) living in Costa Rica between 1994 and 2004, matched for age, sex, and area of residence, were genotyped by restriction fragment-length polymorphism polymerase chain reaction. A food frequency questionnaire was used to assess the intake of caffeinated coffee. MAIN OUTCOME MEASURE: Relative risk of nonfatal MI associated with coffee intake, calculated using unconditional logistic regression.
RESULTS: Fifty-five percent of cases (n = 1114) and 54% of controls (n = 1082) were carriers of the slow *1F allele. For carriers of the slow *1F allele, the multivariate-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) of nonfatal MI associated with consuming less than 1, 1, 2 to 3, and 4 or more cups of coffee per day were 1.00 (reference), 0.99 (0.69-1.44), 1.36 (1.01-1.83), and 1.64 (1.14-2.34), respectively. Corresponding ORs (95% CIs) for individuals with the rapid *1A/*1A genotype were 1.00, 0.75 (0.51-1.12), 0.78 (0.56-1.09), and 0.99 (0.66-1.48) (P = .04 for gene x coffee interaction). For individuals younger than the median age of 59 years, the ORs (95% CIs) associated with consuming less than 1, 1, 2 to 3, or 4 or more cups of coffee per day were 1.00, 1.24 (0.71-2.18), 1.67 (1.08-2.60), and 2.33 (1.39-3.89), respectively, among carriers of the *1F allele. The corresponding ORs (95% CIs) for those with the *1A/*1A genotype were 1.00, 0.48 (0.26-0.87), 0.57 (0.35-0.95), and 0.83 (0.46-1.51).
CONCLUSION: Intake of coffee was associated with an increased risk of nonfatal MI only among individuals with slow caffeine metabolism, suggesting that caffeine plays a role in this association.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16522833     DOI: 10.1001/jama.295.10.1135

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  93 in total

Review 1.  Genetics of caffeine consumption and responses to caffeine.

Authors:  Amy Yang; Abraham A Palmer; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2010-06-09       Impact factor: 4.530

2.  PharmGKB summary: caffeine pathway.

Authors:  Caroline F Thorn; Eleni Aklillu; Ellen M McDonagh; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2012-05       Impact factor: 2.089

3.  Caffeine and blood pressure response: sex, age, and hormonal status.

Authors:  Noha H Farag; Thomas L Whitsett; Barbara S McKey; Michael F Wilson; Andrea S Vincent; Susan A Everson-Rose; William R Lovallo
Journal:  J Womens Health (Larchmt)       Date:  2010-06       Impact factor: 2.681

Review 4.  The role of noninvasive cardiovascular testing, applied clinical nutrition and nutritional supplements in the prevention and treatment of coronary heart disease.

Authors:  Mark Houston
Journal:  Ther Adv Cardiovasc Dis       Date:  2018-01-10

5.  Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans.

Authors:  Roza Ghotbi; Magnus Christensen; Hyung-Keun Roh; Magnus Ingelman-Sundberg; Eleni Aklillu; Leif Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2007-03-17       Impact factor: 2.953

6.  Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson's disease.

Authors:  R A Popat; S K Van Den Eeden; C M Tanner; F Kamel; D M Umbach; K Marder; R Mayeux; B Ritz; G W Ross; H Petrovitch; B Topol; V McGuire; S Costello; A D Manthripragada; A Southwick; R M Myers; L M Nelson
Journal:  Eur J Neurol       Date:  2011-01-31       Impact factor: 6.089

Review 7.  Coffee consumption and cardiovascular health: getting to the heart of the matter.

Authors:  Salome A Rebello; Rob M van Dam
Journal:  Curr Cardiol Rep       Date:  2013-10       Impact factor: 2.931

Review 8.  Biological roles of cytochrome P450 1A1, 1A2, and 1B1 enzymes.

Authors:  Yeo-Jung Kwon; Sangyun Shin; Young-Jin Chun
Journal:  Arch Pharm Res       Date:  2021-01-23       Impact factor: 4.946

Review 9.  Long-term coffee consumption and risk of cardiovascular disease: a systematic review and a dose-response meta-analysis of prospective cohort studies.

Authors:  Ming Ding; Shilpa N Bhupathiraju; Ambika Satija; Rob M van Dam; Frank B Hu
Journal:  Circulation       Date:  2013-11-07       Impact factor: 29.690

Review 10.  From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions.

Authors:  Daniel W Nebert; Ge Zhang; Elliot S Vesell
Journal:  Drug Metab Rev       Date:  2008       Impact factor: 4.518

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.